2023
Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding
Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding. Blood 2023, 142: 2312. DOI: 10.1182/blood-2023-185340.Peer-Reviewed Original ResearchHereditary hemorrhagic telangiectasiaIncremental net monetary benefitIncremental cost-effectiveness ratioEmergency department visitsCare of patientsHemostatic proceduresIron infusionPatient timeBevacizumab therapyDepartment visitsRBC transfusionHemorrhagic telangiectasiaVascular endothelial growth factor inhibitionRed blood cell transfusionEQ-5D index valuesCommon hereditary bleeding disorderLocal hemostatic proceduresRBC transfusion needSystemic bevacizumab therapyHealth resource utilizationBlood cell transfusionWorld Health Organization VigiBaseLong-term followGrowth factor inhibitionCost-saving intervention
2013
Urinary Biomarkers of AKI and Mortality 3 Years after Cardiac Surgery
Coca SG, Garg AX, Thiessen-Philbrook H, Koyner JL, Patel UD, Krumholz HM, Shlipak MG, Parikh CR. Urinary Biomarkers of AKI and Mortality 3 Years after Cardiac Surgery. Journal Of The American Society Of Nephrology 2013, 25: 1063-1071. PMID: 24357673, PMCID: PMC4005309, DOI: 10.1681/asn.2013070742.Peer-Reviewed Original ResearchConceptsKidney injury molecule-1Long-term mortalityIL-18Urinary biomarkersClinical AKICardiac surgeryHighest tertileUrinary neutrophil gelatinase-associated lipocalinProspective long-term followNeutrophil gelatinase-associated lipocalinContinuous net reclassification improvementInjury molecule-1Kidney injury biomarkersPostoperative day 1Gelatinase-associated lipocalinImmediate postoperative periodAdditional prognostic informationLong-term followNet reclassification improvementMortality 3 yearsLiver fatty acidAKI cohortCause mortalityHospital outcomesKidney injury